Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of DENTSPLY Sirona Inc (NASDAQ: XRAY) closed at $11.83 in the last session, down -3.19% from day before closing price of $12.22. In other words, the price has decreased by -$3.19 from its previous closing price. On the day, 6.37 million shares were traded. XRAY stock price reached its highest trading level at $12.185 during the session, while it also had its lowest trading level at $11.69.
Ratios:
We take a closer look at XRAY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.10. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2359894016 and an Enterprise Value of 4510894080. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.64 while its Price-to-Book (P/B) ratio in mrq is 1.20. Its current Enterprise Value per Revenue stands at 1.229 whereas that against EBITDA is 7.206.
Stock Price History:
The Beta on a monthly basis for XRAY is 1.01, which has changed by -0.51575935 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $24.93, while it has fallen to a 52-week low of $12.14. The 50-Day Moving Average of the stock is -12.35%, while the 200-Day Moving Average is calculated to be -24.48%.
Shares Statistics:
According to the various share statistics, XRAY traded on average about 3.33M shares per day over the past 3-months and 3195210 shares per day over the past 10 days. A total of 199.30M shares are outstanding, with a floating share count of 198.20M. Insiders hold about 0.64% of the company’s shares, while institutions hold 101.83% stake in the company. Shares short for XRAY as of 1759190400 were 9536789 with a Short Ratio of 2.86, compared to 1756425600 on 7641849. Therefore, it implies a Short% of Shares Outstanding of 9536789 and a Short% of Float of 5.33.
Dividends & Splits
The forward annual dividend rate for XRAY is 0.64, which was 0.64 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.052373156. The stock’s 5-year Average Dividend Yield is 1.82.
Earnings Estimates
. The current assessment of DENTSPLY Sirona Inc (XRAY) involves the perspectives of 16.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.41.
Analysts are recommending an EPS of between $1.94 and $1.63 for the fiscal current year, implying an average EPS of $1.87. EPS for the following year is $2.03, with 16.0 analysts recommending between $2.3 and $1.93.
Revenue Estimates
According to 15 analysts,. The current quarter’s revenue is expected to be $899.87M. It ranges from a high estimate of $915.8M to a low estimate of $879.3M. As of. The current estimate, DENTSPLY Sirona Inc’s year-ago sales were $951MFor the next quarter, 15 analysts are estimating revenue of $940.6M. There is a high estimate of $975M for the next quarter, whereas the lowest estimate is $906M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.73B in the next fiscal year. The high estimate is $3.84B and the low estimate is $3.64B.
